Silexion Therapeutics Corp. (NASDAQ: SLXN) announced a 1-for-15 reverse share split of its ordinary shares, effective after market close on July 28, 2025. This split aims to enhance Silexion’s capital markets position and support its growth initiatives. Shareholders do not need to take any action, as their shares will be adjusted automatically. The reverse split is intended to help Silexion comply with Nasdaq’s minimum bid price requirement and align with market standards. The Company is focused on developing RNA interference therapies for KRAS-driven cancers, with promising results in preclinical studies and Phase 2 trials for pancreatic cancer.

Read more at GlobeNewswire: Silexion Therapeutics Announces 1-for-15 Reverse Share